Evidence map›Paper›PMID 29172746›Full record

ArticleClinical and experimental hypertension (New York, N.Y. : 1993)2018

Pazopanib for renal cell carcinoma leads to elevated mean arterial pressures in a murine model.

Amber Kempton, Cody Justice, Aaron Guo, Matthew Cefalu, Michael Makara, Paul Janssen, Thai H Ho, Sakima A Smith

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental hypertension (New York, N.Y. : 1993), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. The Impact of Pazopanib on the Cardiovascular System.Journal of cardiovascular pharmacology and therapeutics · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Amber Kemptonc Internal Medicine for Kempton, Davis Heart and Lung Research Institute, The Ohio State University , Columbus , OH , USA.
Cody Justicec Internal Medicine for Kempton, Davis Heart and Lung Research Institute, The Ohio State University , Columbus , OH , USA.
Aaron Guoc Internal Medicine for Kempton, Davis Heart and Lung Research Institute, The Ohio State University , Columbus , OH , USA.
Matthew Cefaluc Internal Medicine for Kempton, Davis Heart and Lung Research Institute, The Ohio State University , Columbus , OH , USA.
Michael Makarac Internal Medicine for Kempton, Davis Heart and Lung Research Institute, The Ohio State University , Columbus , OH , USA.
Paul Janssenb Department of Physiology and Cell Biology , The Ohio State University , Columbus , OH , USA.
Thai H Hod Internal Medicine (Oncology), Mayo Clinic Arizona , Phoenix , AZ , USA.
Sakima A Smitha Department of Internal Medicine (Division of Cardiology) , The Ohio State University College of Medicine , Columbus , OH , USA.

Funding

Defining New Pathways in Heart Failure and ArrhythmiaK08HL135437 · NHLBI · OHIO STATE UNIVERSITY · PI SMITH, SAKIMA AHMAD · 2017 to 2021
$749k
NHLBI NIH HHS K08 HL135437NHLBI NIH HHS L30 HL123325
6 · The paper itself

Abstract

backgroundIn the setting of metastatic RCC (mRCC), pazopanib is approved as first line therapy. Unfortunately treatment may lead to cardiotoxicity such as hypertension, heart failure, and myocardial ischemia.

objectiveDefine the in vivo role of pazopanib in the development of cardiotoxicity.

methodsWild type mice were dosed for 42 days via oral gavage, and separated into control and treatment (pazopanib) groups. Baseline ECG's, echocardiograms, and blood pressures were recorded. At the conclusion of the study functional parameters were again recorded, and animals were used for pathological, histological, and protein analysis.

resultsAfter 2 weeks of dosing with pazopanib, the treatment group exhibited a statistically significant increase in mean arterial pressure compared to control mice (119 ± 11.7 mmHg versus 108 ± 8.2 mmHg, p = 0.049). Treatment with pazopanib led to a significant reduction in the cardiac output of mice.

conclusionOur findings in mice clearly demonstrate that treatment with pazopanib leads to a significant elevation in blood pressure after 2 weeks of dosing and this persists for the duration of dosing. The continued development of the cardio-oncology field will be paramount in providing optimal oncologic care while simultaneously improving cardiac outcomes through further investigation into the mechanisms of CV toxicity.

Indexed as

Angiogenesis InhibitorsAnimalsArterial PressureBody WeightCarcinoma, Renal CellCardiac OutputDisease Models, AnimalEchocardiographyElectrocardiographyHeartHypertensionIndazolesKidneyKidney NeoplasmsMiceMyocardiumAngiogenesis InhibitorsIndazolespazopanibPyrimidinesReceptor, Angiotensin, Type 1Receptor, Angiotensin, Type 2SulfonamidesVascular Endothelial Growth Factor Avascular endothelial growth factor A, mousecardio-oncologyhypertensionpazopanibRenal cell carcinomatyrosine kinase inhibitors

Identifiers

PMID29172746
PMCPMC6203326

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.